Two views better than one in chest X-ray AI for classifying adenopathy: Study

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-09-24 04:30 GMT   |   Update On 2021-09-24 06:28 GMT

USA: A recent study has shown an artificial intelligence (AI) model, that analyzes both frontal and lateral, to be a better performer for classifying adenopathy. The study findings were presented Conference on Machine Intelligence in Medical Imaging (C-MIMI) on September 20, 2021. Researchers from Johns Hopkins University found that the combined algorithm yielded the best results for...

Login or Register to read the full article

USA: A recent study has shown an artificial intelligence (AI) model, that analyzes both frontal and lateral, to be a better performer for classifying adenopathy. The study findings were presented Conference on Machine Intelligence in Medical Imaging (C-MIMI) on September 20, 2021. 

Researchers from Johns Hopkins University found that the combined algorithm yielded the best results for classifying thoracic adenopathy. They had hypothesized that a deep-learning model that was trained on both frontal and lateral chest radiographs would perform better than a model that's trained on only one type of images.

Ishan Mazumdar, a second-year medical student said, "This is actually analogous to the common practice of radiologists who use both projections -- frontal and lateral -- to glean synergistic diagnostic details." 

"This is actually analogous to the common practice of radiologists who use both projections -- frontal and lateral -- to glean synergistic diagnostic details," said presenter Ishan Mazumdar, a second-year medical student.

To test the hypothesis, they collected training and validation set from the PadChest dataset of radiographs, as well as Radiopedia for additional radiographs of hilar adenopathy specifically in patients with sarcoidosis. Ultimately, a training set of 2,107 paired frontal and lateral chest x-rays were used to train the models. 

The researchers opted for a two-step deep convolutional neural network pipeline. In the first step, an object detection model was used to detect and crop the hilum on the radiographs. A hilum classification algorithm then classified the cropped image as having thoracic adenopathy or not.

They then tested the models on an external test set of 129 paired radiographs from patients at Johns Hopkins University who were diagnosed with sarcoidosis involving any organ. The test set had a higher prevalence of hilar adenopathy compared with the general population. For the purposes of the study, the ground truth was determined by board-certified thoracic radiologists after reviewing contemporaneous chest CT images.   

The performance of each model was averaged over 10 testing "runs."

The researchers demonstrated an improvement in diagnostic accuracy when using deep-learning models trained using both frontal and lateral chest x-rays. 

In addition to hilar adenopathy, other chest pathologies may also be better detected on the lateral projection, according to Mazumdar.

"Therefore, deep-learning models that ignore the lateral chest radiographs are not taking full advantage of commonly available data," he said.

Mazumdar acknowledged the limitations of their study, such as the inclusion in the training set of radiographs of patients with any type of adenopathy -- not just from sarcoidosis. This likely lowered the diagnostic performance of the algorithm, as the test set specifically included patients with sarcoidosis, he said.

Also, the ground truth for adenopathy is difficult to establish and subject to interobserver variability, and the optimal method of combining frontal and lateral chest x-rays isn't yet known, he said.

In the next phase of their work, the researchers plan to investigate different deep-learning methods for generating combined frontal and lateral predictions.

Tags:    
Article Source : Conference on Machine Intelligence in Medical Imaging

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News